Viking Therapeutics: Undervalued by 89.2% According to DCF Analysis

Viking Therapeutics has seen a 6.3% decline in share price over the last 7 days, a 17.0% decline over 30 days, and a 9.1% decline over 1 year. However, the company has a 3-year gain of 195.3% and a 5-year gain of 223.9%. The valuation score is 3 out of 6, indicating it screens as undervalued on half of the valuation checks. The discounted cash flow model suggests the stock is 89.2% undervalued based on its intrinsic value of $273.00 per share.